Profound Medical Corp.

3080 Yonge Street, Suite 4040
Toronto
Ontario
M4N 3N1Toronto
Canada

Tel: 647-476-1350

Show jobs for this employer

40 articles with Profound Medical Corp.

  • Profound Medical Corp., the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging, thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, will announce its third quarter 2020 financial results after market close on Thursday, November 5, 2020.

  • Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, announced today that management will present an update on the Company’s business at the Cantor Virtual Global Healthcare Conference

  • Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, announced today that management will present an update on the Company’s business at the Canaccord Genuity 40th Annual Growth Conference

  • Profound Medical Corp., the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging, thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, reported financial results for the second quarter ended June 30, 2020, and provided an update on its operations.

  • Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, will announce its second quarter 2020 financial results after market close on Thursday, August 6, 2020.

  • Profound Medical Corp. is pleased to announce that it has closed its previously-announced underwritten offering of common shares of the Company at a price of US$14.50 per Common Share.

  • Profound Medical Corp. is pleased to announce the pricing of an underwritten public offering of 2,758,621 common shares of the Company, at a price of US$14.50 per Common Share.

  • Profound Medical Corp. is pleased to announce that it intends to file a preliminary prospectus supplement to its short form base shelf prospectus dated October 17, 2019 in the United States and Canada relating to a proposed marketed public offering of common shares of the Company.

  • Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual and Special Meeting of Shareholders that was held today (the “Meeting”).

  • Profound Medical Corp., the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging, thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, reported financial results for the first quarter ended March 31, 2020, and provided an update on its operations.

  • Profound Medical Corp. will announce its first quarter 2020 financial results after market close on Thursday, May 7, 2020.

  • Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2019.

  • Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, announced today that management will participate in two investor conferences in March.

  • Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, will announce its fourth quarter and full year 2019 financial results after market close on Tuesday, March 3, 2020.

  • Profound Medical Corp. announced that it has retired its $12.5 million in principal amount loan with Canadian Imperial Bank of Commerce, maturing on July 29, 2022.

  • Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce that it has closed its previously-announced underwritten offering (the “Offering”) of common shares of the Company (the “Common Shares”) at a price of US$11.65 per Common Share.

  • Profound Medical Corp. (TSX:PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the pricing of an underwritten public offering (the “Offering”) of 2,950,000 common shares of the Company (the “Common Shares”), at a price of US$11.65 per Common Share (the “Offering Price”).

  • Profound Medical Corp. is pleased to announce that it intends to file a preliminary prospectus supplement to its short form base shelf prospectus dated October 17, 2019 in the United States and Canada relating to a proposed marketed public offering of common shares of the Company.

  • Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”), a commercial-stage medical device company focused on customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, today announced preliminary unaudited revenues for the fourth quarter and full year 2019

  • Profound Medical Corp. announced the signing of its first-ever U.S. multi-site imaging center agreement for TULSA-PRO® with RadNet, Inc., a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 340 owned and/or operated outpatient imaging centers.